NCT04003519View on ClinicalTrials.gov

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

April 30, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

December 30, 2023

Conditions
Acromegaly
Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT04003519 - Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly | Biotech Hunter | Biotech Hunter